These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1186 related articles for article (PubMed ID: 10720049)

  • 21. Monitoring of growth hormone replacement therapy in adults, based on measurement of serum markers.
    de Boer H; Blok GJ; Popp-Snijders C; Stuurman L; Baxter RC; van der Veen E
    J Clin Endocrinol Metab; 1996 Apr; 81(4):1371-7. PubMed ID: 8636336
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Different effects of short- and long-term recombinant hGH administration on ghrelin and adiponectin levels in GH-deficient adults.
    Giavoli C; Cappiello V; Corbetta S; Ronchi CL; Morpurgo PS; Ferrante E; Beck-Peccoz P; Spada A
    Clin Endocrinol (Oxf); 2004 Jul; 61(1):81-7. PubMed ID: 15212648
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A switch from oral (2 mg/day) to transdermal (50 microg/day) 17beta-estradiol therapy increases serum insulin-like growth factor-I levels in recombinant human growth hormone (GH)-substituted women with GH deficiency.
    Janssen YJ; Helmerhorst F; Frölich M; Roelfsema F
    J Clin Endocrinol Metab; 2000 Jan; 85(1):464-7. PubMed ID: 10634425
    [TBL] [Abstract][Full Text] [Related]  

  • 24. IGF-I and IGF binding protein-3 levels during initial GH dosage step-up are indicators of GH sensitivity in GH-deficient children and short children born small for gestational age.
    Ranke MB; Traunecker R; Martin DD; Schweizer R; Schwarze CP; Wollmann HA; Binder G
    Horm Res; 2005; 64(2):68-76. PubMed ID: 16113581
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bone density and turnover in young adult patients with growth hormone deficiency after 2-year growth hormone replacement according with gender.
    Rota F; Savanelli MC; Tauchmanova L; Savastano S; Lombardi G; Colao A; Di Somma C
    J Endocrinol Invest; 2008 Feb; 31(2):94-102. PubMed ID: 18362499
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Body composition and physical fitness are major determinants of the growth hormone-insulin-like growth factor axis aberrations in adult Turner's syndrome, with important modulations by treatment with 17 beta-estradiol.
    Gravholt CH; Naeraa RW; Fisker S; Christiansen JS
    J Clin Endocrinol Metab; 1997 Aug; 82(8):2570-7. PubMed ID: 9253336
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women.
    Khorram O; Laughlin GA; Yen SS
    J Clin Endocrinol Metab; 1997 May; 82(5):1472-9. PubMed ID: 9141536
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reduced androgen levels in adult turner syndrome: influence of female sex steroids and growth hormone status.
    Gravholt CH; Svenstrup B; Bennett P; Sandahl Christiansen J
    Clin Endocrinol (Oxf); 1999 Jun; 50(6):791-800. PubMed ID: 10468952
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of the selective estrogen receptor modulator, raloxifene, on the somatotropic axis and insulin-glucose homeostasis.
    Oleksik AM; Duong T; Pliester N; Asma G; Popp-Snijders C; Lips P
    J Clin Endocrinol Metab; 2001 Jun; 86(6):2763-8. PubMed ID: 11397884
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A low starting dose of genotropin in growth hormone-deficient adults.
    Janssen YJ; Frölich M; Roelfsema F
    J Clin Endocrinol Metab; 1997 Jan; 82(1):129-35. PubMed ID: 8989246
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Administration route-dependent effects of estrogens on IGF-I levels during fixed GH replacement in women with hypopituitarism.
    van der Klaauw AA; Biermasz NR; Zelissen PM; Pereira AM; Lentjes EG; Smit JW; van Thiel SW; Romijn JA; Roelfsema F
    Eur J Endocrinol; 2007 Dec; 157(6):709-16. PubMed ID: 18057377
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Serum insulin-like growth factor I (IGF-I), IGF-binding protein-1 and -3, and the acid-labile subunit as serum markers of body composition during growth hormone (GH) therapy in adults with GH deficiency.
    Thorén M; Hilding A; Baxter RC; Degerblad M; Wivall-Helleryd IL; Hall K
    J Clin Endocrinol Metab; 1997 Jan; 82(1):223-8. PubMed ID: 8989263
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of replacement dose of dehydroepiandrosterone in men and women of advancing age.
    Morales AJ; Nolan JJ; Nelson JC; Yen SS
    J Clin Endocrinol Metab; 1994 Jun; 78(6):1360-7. PubMed ID: 7515387
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Influence of some biological indexes on sex hormone-binding globulin and androgen levels in aging or obese males.
    Vermeulen A; Kaufman JM; Giagulli VA
    J Clin Endocrinol Metab; 1996 May; 81(5):1821-6. PubMed ID: 8626841
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Divergent effect of endogenous and exogenous sex steroids on the insulin-like growth factor I response to growth hormone in short normal adolescents.
    Coutant R; de Casson FB; Rouleau S; Douay O; Mathieu E; Gatelais F; Bouhours-Nouet N; Voinot C; Audran M; Limal JM
    J Clin Endocrinol Metab; 2004 Dec; 89(12):6185-92. PubMed ID: 15579776
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Contrasting effects of oral and transdermal routes of estrogen replacement therapy on 24-hour growth hormone (GH) secretion, insulin-like growth factor I, and GH-binding protein in postmenopausal women.
    Weissberger AJ; Ho KK; Lazarus L
    J Clin Endocrinol Metab; 1991 Feb; 72(2):374-81. PubMed ID: 1991807
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Short-term safety and efficacy of human GH replacement therapy in 595 adults with GH deficiency: a comparison of two dosage algorithms.
    Kehely A; Bates PC; Frewer P; Birkett M; Blum WF; Mamessier P; Ezzat S; Ho KK; Lombardi G; Luger A; Marek J; Russell-Jones D; Sönksen P; Attanasio AF
    J Clin Endocrinol Metab; 2002 May; 87(5):1974-9. PubMed ID: 11994327
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A dose-response study of growth hormone (GH) replacement on whole body protein and lipid kinetics in GH-deficient adults.
    Lucidi P; Lauteri M; Laureti S; Celleno R; Santoni S; Volpi E; Angeletti G; Santeusanio F; De Feo P
    J Clin Endocrinol Metab; 1998 Feb; 83(2):353-7. PubMed ID: 9467540
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term skeletal effects of recombinant human growth hormone (rhGH) alone and rhGH combined with alendronate in GH-deficient adults: a seven-year follow-up study.
    Biermasz NR; Hamdy NA; Pereira AM; Romijn JA; Roelfsema F
    Clin Endocrinol (Oxf); 2004 May; 60(5):568-75. PubMed ID: 15104559
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The effect of recombinant human growth hormone on regulation of growth hormone secretion and blood glucose in insulin-dependent diabetes.
    Wurzburger MI; Prelevic GM; Sönksen PH; Balint-Peric LA; Wheeler M
    J Clin Endocrinol Metab; 1993 Jul; 77(1):267-72. PubMed ID: 8325951
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 60.